financetom
Business
financetom
/
Business
/
BRIEF-ReShape Lifesciences Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-ReShape Lifesciences Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
Apr 7, 2025 2:09 PM

April 7 (Reuters) - ReShape Lifesciences Inc ( RSLS ):

* RESHAPE LIFESCIENCES® REPORTS YEAR ENDED DECEMBER 31, 2024

FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* RESHAPE LIFESCIENCES INC ( RSLS ): MERGER AGREEMENT WITH VYOME

THERAPEUTICS AND ASSET PURCHASE AGREEMENT WITH BIORAD MEDISYS

REMAIN ON TRACK

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Building products maker HNI to acquire Steelcase for $2.2 billion
Building products maker HNI to acquire Steelcase for $2.2 billion
Aug 4, 2025
Aug 4 (Reuters) - Building products makwer HNI has entered an agreement to acquire peer Steelcase ( SCS ) in a cash and stock transaction, with a total consideration of about $2.2 billion, HNI said on Monday. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Krystal Biotech's Q2 revenue rises 37% to $96 mln
Krystal Biotech's Q2 revenue rises 37% to $96 mln
Aug 4, 2025
Overview * Krystal Biotech ( KRYS ) Q2 product revenue rises to $96 mln, driven by VYJUVEK sales * Net income for Q2 increases to $38.3 mln, reflecting strong operational performance * VYJUVEK approved in Japan, enhancing global expansion efforts Outlook * Krystal Biotech ( KRYS ) expects VYJUVEK Japan launch by end of 2025 * Company plans VYJUVEK Germany...
Chemours, DuPont, Corteva to settle environmental claims with New Jersey
Chemours, DuPont, Corteva to settle environmental claims with New Jersey
Aug 4, 2025
Aug 4 (Reuters) - Chemours ( CC ), DuPont ( DD ) and Corteva ( CTVA ) said on Monday they have reached an agreement with the state of New Jersey in various litigation matters including PFAS chemicals and other state directives. Under the settlement, the companies will pay a total of $875 million over a 25-year period. Lawsuits accusing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved